AUTHORS

Real Money authors - Bruce Kamich

Bruce Kamich

Bruce Kamich is TheStreet's in-house technical analyst with a 43 year career with a number of bulge bracket firms like Morgan Stanley, Smith Barney Harris Upham, and Merrill Lynch. Along the way he accumulated knowledge about the fundamentals of the commodity markets, interest rates, equities and ETFs. 

In addition to writing for theStreet.com Kamich has been teaching technical analysis at Baruch College for the past twenty years.

Kamich was one of the earliest Chartered Market Technicians  or CMTs, a professional designation similar to the CFA title. He has authored two books on charting and technical analysis - "How Technical Analysis Works"  and "Chart Patterns." He is a two-time past president of the Market Technicians Association (now called the CMTA), the professional organization for chartists worldwide. He was also the president of the Market Technicians Association Educational Foundation (MTAEF.org).
Email Bruce Kamich

Recent Articles By The Author

Is Live Ventures Taking Notes From GameStop?

Let's see what we might glean from the charts.

Ranpak Holdings May Double or More in 2021

Here's what aggressive traders should look for.

Let's Dare to Take Another Look at GameStop

Here's what we found in the latest GME charts.

How Far Can Traders Go 'Beyond' This Pepsi Deal?

Beyond Meat is rising after a partnership with Pepsi was announced. Let's check the charts.

Abbott Labs Has the Formula for a Long Trade

ABT has made an upside breakout on the daily Point and Figure chart, and here's how investors can make their next move.

The Housing Market Is Hot and Home Depot Is Poised to Make New Highs

We're in the middle of one of the best housing markets ever as people upgrade to homes away from cities.

Clorox Is Ready to Clean Up as the Downtrend Has Been Broken

Let's review the charts and indicators.

Boot Barn Is Kickin' It, but Wait for a Correction to Saddle Up

The indicators for the western apparel retailer are bullish, but prices are extended compared to the longer-term moving averages, so be cautious.

GoodRx Needs a Shot in the Arm to Improve Its Outlook

IPOs in recent months have done extremely well -- not so GDRX.

Looking for Higher Highs After a Trex Correction

Some new accumulation (buying) around the $85 area should set the stage for further gains.

Email sent

Thank you, your email to has been sent successfully.

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight